

# Histiocytosis UK

known as

Histio UK

**Annual Report and Financial Statements**

**for the Year Ended 31 March 2022**

# **Histiocytosis UK**

## **Contents**

Reference and Administrative Details	1
Trustees' Report	2 to 6
Statement of Trustees' Responsibilities	7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Notes to the Financial Statements	11 to 16

# Histiocytosis UK

## Reference and Administrative Details

<b>Trustees</b>	Mr A Kontoyannis, Chair Prof. P Beverley Dr V Nanduri Mr P Bienenstock Prof. M Collin Dr C Booth Dr R Tattersall (Appointed 18 November 2021)
<b>Other Officers</b>	Lynn Jackson, Executive Director
<b>Principal Office</b>	PO Box 159 Liskeard Cornwall PL14 9DQ
<b>Charity Registration Number</b>	1158789
<b>Bankers</b>	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ
<b>Independent Examiner</b>	TC Group 33 Boston Road Holbeach Spalding Lincolnshire PE12 7LR

# Histiocytosis UK

## Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 31 March 2022.

### Objectives and activities

#### *Public benefit*

☐ The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:

☐ (i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytotic diseases, the useful results of which will be disseminated for the public benefit;

☐ (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;

☐ (iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;

☐ (iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research.

The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

### Financial Report

#### *Investment policy and objectives*

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

# **Histiocytosis UK**

## **Trustees' Report**

### ***Financial review***

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

### ***Income & Expenditure Summary***

The 2021-2022 income improved slightly against the previous financial year.

We thank all of our generous donors, the individuals, community groups, schools, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

### ***Grant Awards***

In the light of the continued restrictions across not only the UK but around the world this year the Charity focused on the ongoing development of the UK Histiocytosis Registry project and awarded a further £11,084.

### ***Grants Received***

Nil

### **Chairman's Statement**

#### ***Financial***

Income this year has shown an improvement against 2020 enabling the Charity work to continue in these challenging times.

The Covid-19 pandemic continued to reduce the number of opportunities available to us all for fundraising, added to this our supporters faced the challenges of "lockdown" working and the rise in inflation rates. This contributed to reducing the pound in all of our pockets, as always, our supporters have risen to this challenge and enabled our continued work.

As we look back over this year's operation, we reflect on the amazing support that we have received during this second year of adversity, which remains a very difficult period for all.

Despite reduced income we have been able to continue our Information Support services and announce a Further Research award of £11,084 to the UK Histiocytosis Registry project - lead by Prof M. Collin.

In memory of our very good friend, colleague and Trustee we launched the Johannes Visser Invited Speaker Award for Clinicians and Researchers.

We are very pleased to have continued and further developed our various Histiocytic information guides and social media platforms allowing us to engage further with our Parents Patients and Supporters.

In association with our partners, we will continue to support histiocytic professionals, patients and families with up-to-date information on these devastating disorders as it becomes available.

Thank you all.

### ***Partnerships***

**Hi-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration**  
Histo UK continues to provide administrative support to this amazing group.

### ***Awareness***

**Histiocytosis UK 2021 - Virtual Forum on 18th November 2021**

## **Histiocytosis UK**

### **Trustees' Report**

The format of this years programme for the Virtual Forum changed to include the delivery of Abstracts, enabling a platform for not only established specialists but introduced emerging new talent in the field of Histiocytic disorders to a specialists audience from the UK and around the world.

#### **Langerhans Cell Histiocytosis (LCH and Other Rarer) - Host Prof. Matthew Collin**

**Dr. Hanhua LIU - Presenting:** Incidence & Survival of Langerhans Cell Histiocytosis: A National Registry Study in England 2013-2018

#### **Abstracts**

**Dr. Vassilios Papadakis & Dr. Marina Servitzoglou -** Greek Paediatric LCH National Registry Results over the last two decades.

**Dr. Samir Patel -** A Relapsing Disease Description RDD

#### **Presentations**

##### **Dr. Eli Diamond**

Member of the interdisciplinary team at Memorial Sloan Kettering treating and studying patients with histiocytic disorders such as Erdheim-Chester disease and Langerhans cell histiocytosis. Clinical Expertise - Neuro-Oncology; Adult Brain Tumours; Histiocytosis.

**Presenting:** Targeted treatment of histiocytosis in adults

#### **Haemophagocytic lymphohistiocytosis (HLH) - Host: Dr Claire Booth**

**Dr Mark Bishton -** Consultant Haematologist, Nottinghamshire University Hospitals Trust. **Dr. Hanhua Liu -** Senior Cancer Intelligence Analyst, Public Health England. **Peter Stilwell -** Senior Data Analyst, Public Health England.

**Presenting:** Histiocytic disease: NDRS approach to understanding rare disease and cancer at a population level

#### **Abstracts**

**Andrew Duncombe -** In A Single Large Centre Observational Cohort Study Of Hospitalised Covid-19 Patients, Secondary Hlh (Shlh) Was Rare But Hyperinflammation (Hi) Common And Hi Severity Predicted Response To Early Intervention With Dexamethasone Assessed By Day 28 Mortality.

**Joseph Guppy -** A Case Of Macrophage Activation Syndrome (Mas)/Haemophagocytic Lymphohistiocytosis (Hlh) Requiring Extra-Corporeal Membrane Oxygenation In A Patient With Severe Multisystem Lupus Erythematosus

**Jerónimo Moreno-Cuesta -** Hemophagocytes In Covid-19 Disease: A Novel Pilot Study Using Cellsievetm Liquid Biopsy

#### **HLH in Practice including HHASC representatives**

**Dr. Rob Sandler -** Rheumatology Registrar, Sheffield Teaching Hospitals - Presenting: HLH after Bone Marrow Transplant

**Dr Naina McCann -** Infectious Diseases Registrar and Dr Pratyasha Saha Internal Medicine Speciality Trainee, University College London Hospital - Presenting: Complications and causes of death in HLH

**Dr. Harry Wilson -** Morkeh - Rheumatology Registrar, Hammersmith Hospital - Presenting: HLH in pregnancy

#### **Presentations**

**Dr. Rebecca Marsh -** Member of the paediatric haematologist-oncologist team affiliated with Cincinnati Children's Hospital Medical Center. - Presenting: Quercetin Suppresses XIAP Deficiency Associated Hyperinflammation

#### **Plans for the future**

Histio UK, will remain at the forefront in challenging these devastating disorders, we will continue to build on the transfer of information and knowledge available nationally and international through our committee structure to parents, patients and medical professionals.

# Histiocytosis UK

## Trustees' Report

### **Structure, governance and management**

#### ***Organisational structure***

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

#### **The Chair of the SRB for 2021-2022**

Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath.

#### **Vice-Chair**

Professor Peter Beverley MBBS, DSc, FMedSci.

The Trustees review on a regular basis both to recruit new Trustee(s) for their experience, empathy and knowledge of the charity and to keep the skills and composition of the Trustee body and succession planning under review.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

#### ***Fundraising Regulation***

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

#### ***Risk management***

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.

## Histiocytosis UK

### Trustees' Report

#### Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

The annual report was approved by the trustees of the charity on ..... and signed on its behalf by:

Mr A Kontoyannis  
Chair





## Histiocytosis UK

### Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.


The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on ..... and signed on its behalf by:

Mr A Kontoyannis  
Trustee



## **Histiocytosis UK**

### **Independent Examiner's Report to the trustees of Histiocytosis UK**

I report on the accounts of the charity for the year ended 31 March 2022 which are set out on pages 9 to 16.

#### **Respective responsibilities of trustees and examiner**

The trustees are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

#### **Basis of independent examiner's report**

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the next statement.

#### **Independent examiner's statement**

In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Christopher McKenna ACA

TC Group

Holbeach  
Spalding  
Lincolnshire  
PE12 7LR

Date:.....

## Histiocytosis UK

### Statement of Financial Activities for the Year Ended 31 March 2022

	Note	Unrestricted £	Total 2022 £	Total 2021 £
<b>Income and Endowments from:</b>				
Charitable activities	2	166,787	166,787	121,530
Investment income	3	<u>34</u>	<u>34</u>	<u>91</u>
Total Income		<u>166,821</u>	<u>166,821</u>	<u>121,621</u>
<b>Expenditure on:</b>				
Raising funds	4	(1,791)	(1,791)	(1,173)
Research grants awarded	5	(11,084)	(11,084)	(82,562)
Charitable activities	6	<u>(84,518)</u>	<u>(84,518)</u>	<u>(83,555)</u>
Total Expenditure		<u>(97,393)</u>	<u>(97,393)</u>	<u>(167,290)</u>
Net movement in funds		69,428	69,428	(45,669)
<b>Reconciliation of funds</b>				
Total funds brought forward		<u>358,376</u>	<u>358,376</u>	<u>404,045</u>
Total funds carried forward	13	<u>427,804</u>	<u>427,804</u>	<u>358,376</u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2021 is shown in note 13.

# Histiocytosis UK

(Registration number: 1158789)  
Balance Sheet as at 31 March 2022

	Note	2022 £	2021 £
<b>Fixed assets</b>			
Tangible assets	10	1,893	904
<b>Current assets</b>			
Debtors	11	762	686
Cash at bank and in hand		<u>428,188</u>	<u>359,569</u>
		428,950	360,255
<b>Creditors: Amounts falling due within one year</b>	12	<u>(3,039)</u>	<u>(2,783)</u>
<b>Net current assets</b>		<u>425,911</u>	<u>357,472</u>
<b>Net assets</b>		<u>427,804</u>	<u>358,376</u>
<b>Funds of the charity:</b>			
<b>Unrestricted income funds</b>			
Unrestricted		<u>427,804</u>	<u>358,376</u>
<b>Total funds</b>	13	<u>427,804</u>	<u>358,376</u>

The financial statements on pages 9 to 16 were approved by the trustees, and authorised for issue on ..... and signed on their behalf by:

Mr A. Kontoyannis  
Chair

# Histiocytosis UK

## Notes to the Financial Statements for the Year Ended 31 March 2022

### 1 Accounting policies

#### Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

#### Basis of preparation

Histiocytosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

#### Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

#### Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

#### Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the Charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

#### Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

#### Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

#### Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

#### Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

#### Tangible fixed assets

Individual fixed assets costing £100.00 or more are initially recorded at cost.

# Histiocytosis UK

## Notes to the Financial Statements for the Year Ended 31 March 2022

### Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Office equipment	33% reducing balance

### Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that the will not be able to collect all amounts due according to the original terms of the receivables.

### Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

### Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

### Financial instruments

#### Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

#### Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

# Histiocytosis UK

## Notes to the Financial Statements for the Year Ended 31 March 2022

### 2 Income from charitable activities

	Unrestricted		
	General	Total	Total
	£	2022	2021
		£	£
Donations	166,412	166,412	84,970
Gift aid tax reclaimed	375	375	-
Lottery fund	-	-	36,560
	<u>166,787</u>	<u>166,787</u>	<u>121,530</u>

The total income from charitable activities for the year was £166,787 (2021 - £121,530) of which £166,787 (2021 - £84,970) was attributable to unrestricted funds and £Nil (2021 - £36,560) to restricted funds.

### 3 Investment income

	Unrestricted		
	funds	Total	Total
	General	2022	2021
	£	£	£
Interest receivable and similar income;			
Interest receivable on bank deposits	<u>34</u>	<u>34</u>	<u>91</u>

The total investment income for the year was £34 (2021 - £91) of which £34 (2021 - £91) was attributable to unrestricted funds and £Nil (2021 - £Nil) to restricted funds.

### 4 Expenditure on raising funds

	Unrestricted		
	funds	Total	Total
	General	2022	2021
	£	£	£
General fundraising and events expenses	<u>1,791</u>	<u>1,791</u>	<u>1,173</u>

The total expenditure on raising funds for the year was £1,791 (2021 - £1,173) of which £1,791 (2021 - £1,173) was attributable to unrestricted funds and £Nil (2021 - £Nil) to restricted funds.

### 5 Expenditure on research grants awarded

	Unrestricted		
	funds	Total	Total
	General	2022	2021
	£	£	£
Research costs	<u>11,084</u>	<u>11,084</u>	<u>82,562</u>
	<u>11,084</u>	<u>11,084</u>	<u>82,562</u>

The total expenditure on research grants awarded for the year was £11,084 (2021 - £82,562) of which £11,084 (2021 - £82,562) was attributable to unrestricted funds and £Nil (2021 - £Nil) to restricted funds.

# Histiocytosis UK

## Notes to the Financial Statements for the Year Ended 31 March 2022

### 6 Expenditure on charitable activities

		Unrestricted	Total	Total
	Note	General	2022	2021
		£	£	£
Travelling		1,957	1,957	1,333
Insurance		940	940	901
Telephone		1,667	1,667	895
Computer expenses		3,877	3,877	1,716
Printing, postage, stationery and advertising		3,530	3,530	3,321
Accountancy fees		1,404	1,404	1,422
Bank charges		106	106	69
Depreciation		933	933	444
Staff costs	8	56,914	56,914	48,957
Outreach costs		13,190	13,190	24,497
		<u>84,518</u>	<u>84,518</u>	<u>83,555</u>

The total expenditure on charitable activities for the year was £84,518 (2021 - £83,555) of which £84,518 (2021 - £46,995) was attributable to unrestricted funds and £Nil (2021 - £36,560) to restricted funds.

### 7 Net incoming/outgoing resources

Net incoming/(outgoing) resources for the year include:

	2022	2021
	£	£
Depreciation of fixed assets	<u>933</u>	<u>444</u>

### 8 Staff costs

The aggregate payroll costs were as follows:

	2022	2021
	£	£
Staff costs during the year were:		
Wages and salaries	<u>56,914</u>	<u>48,957</u>

No employee received emoluments of more than £60,000 during the year.

### 9 Taxation

The charity is a registered charity and is therefore exempt from taxation.



# Histiocytosis UK

## Notes to the Financial Statements for the Year Ended 31 March 2022

### 10 Tangible fixed assets

	Office equipment £	Total £
<b>Cost</b>		
At 1 April 2021	3,568	3,568
Additions	1,922	1,922
At 31 March 2022	5,490	5,490
<b>Depreciation</b>		
At 1 April 2021	2,664	2,664
Charge for the year	933	933
At 31 March 2022	3,597	3,597
<b>Net book value</b>		
At 31 March 2022	1,893	1,893
At 31 March 2021	904	904

### 11 Debtors

	2022 £	2021 £
Prepayments	762	686

### 12 Creditors: amounts falling due within one year

	2022 £	2021 £
Other taxation and social security	1,635	1,379
Accruals	1,404	1,404
	3,039	2,783

### 13 Funds

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
<b>Unrestricted</b>				
General	358,376	166,821	(97,393)	427,804

## Histiocytosis UK

### Notes to the Financial Statements for the Year Ended 31 March 2022

	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
<b>Unrestricted</b>				
General	404,045	85,061	(130,730)	358,376
<b>Restricted</b>	-	36,560	(36,560)	-
<b>Total funds</b>	<u>404,045</u>	<u>121,621</u>	<u>(167,290)</u>	<u>358,376</u>

#### 14 Analysis of net assets between funds

	Unrestricted funds General £	Total funds at 31 March 2022 £
Tangible fixed assets	1,893	1,893
Current assets	428,950	428,950
Current liabilities	(3,039)	(3,039)
<b>Total net assets</b>	<u>427,804</u>	<u>427,804</u>

## Document Activity Report

**Document Sent** Fri, 29 Apr 2022 14:42:48 GMT

**Document Approval Status** Pending

### Approval Activity Summary

Lynn Jackson Pending

### Document Activity History

Document history shows most recent activity first

Date	Activity
------	----------

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

<https://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>

## Document Activity Report

**Document Sent**

Tue, 14 Jun 2022 09:13:06 GMT

### Document Activity History

Document history shows most recent activity first

**Date**

**Activity**

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

**<http://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>**